Spero Therapeutics Inc SPRO shares are trading higher by 120% to $1.60 during Tuesday's trading session after the company received minutes from a Type A meeting with the FDA discussing steps required to resubmit the marketing application for tebipenem HBr.
What Happened?
During the Type A meeting, the FDA indicated that positive results from an additional Phase 3 trial supported by confirmatory nonclinical efficacy evidence could be sufficient to support the approval of tebipenem HBr for cUTI, including pyelonephritis for a limited use indication...Read More
See Also: Here's Why HyreCar Shares Are Skyrocketing Over 50% Higher Tuesday
According to data from Benzinga Pro, Spero Therapeutics has a 52-week high of $19.87 and a 52-week low of $0.68.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
